Free Trial

BioCardia (BCDA) Competitors

BioCardia logo
$2.35 +0.04 (+1.73%)
Closing price 04:00 PM Eastern
Extended Trading
$2.37 +0.02 (+0.64%)
As of 04:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BCDA vs. EGRX, GANX, RNXT, OSTX, GRCE, NBRV, PRLD, ELYM, KLRS, and AADI

Should you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Eagle Pharmaceuticals (EGRX), Gain Therapeutics (GANX), RenovoRx (RNXT), OS Therapies (OSTX), Grace Therapeutics (GRCE), Nabriva Therapeutics (NBRV), Prelude Therapeutics (PRLD), Eliem Therapeutics (ELYM), Kalaris Therapeutics (KLRS), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

BioCardia vs. Its Competitors

BioCardia (NASDAQ:BCDA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Eagle Pharmaceuticals has higher revenue and earnings than BioCardia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCardia$60K215.42-$7.95M-$2.33-1.01
Eagle Pharmaceuticals$257.55M0.19$35.64MN/AN/A

20.6% of BioCardia shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eagle Pharmaceuticals' return on equity of 0.00% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
BioCardiaN/A -30,792.60% -223.06%
Eagle Pharmaceuticals N/A N/A N/A

BioCardia has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

In the previous week, BioCardia had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for BioCardia and 0 mentions for Eagle Pharmaceuticals. BioCardia's average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that BioCardia is being referred to more favorably in the media.

Company Overall Sentiment
BioCardia Very Positive
Eagle Pharmaceuticals Neutral

BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 963.83%. Given BioCardia's stronger consensus rating and higher probable upside, research analysts clearly believe BioCardia is more favorable than Eagle Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCardia
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
Eagle Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

BioCardia and Eagle Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BCDA vs. The Competition

MetricBioCardiaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.71M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-1.0121.0428.0720.05
Price / Sales215.42284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book13.068.378.665.87
Net Income-$7.95M-$55.19M$3.25B$258.55M
7 Day Performance5.38%5.89%4.20%2.23%
1 Month Performance4.44%17.63%10.82%12.76%
1 Year Performance-20.34%5.09%34.70%19.36%

BioCardia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BCDA
BioCardia
3.4971 of 5 stars
$2.35
+1.7%
$25.00
+963.8%
-18.7%$12.71M$60K-1.0140Positive News
EGRX
Eagle Pharmaceuticals
2.4345 of 5 stars
$3.70
+0.3%
N/A-31.4%$48.05M$257.55M0.00100Gap Down
GANX
Gain Therapeutics
2.3561 of 5 stars
$1.58
-0.3%
$8.20
+419.0%
+55.6%$47.66M$50K-1.8420Gap Up
RNXT
RenovoRx
2.2149 of 5 stars
$1.29
-0.8%
$7.25
+462.0%
+4.8%$47.54M$40K-3.236
OSTX
OS Therapies
2.0616 of 5 stars
$1.69
+3.0%
$18.00
+965.1%
N/A$47.49MN/A-1.97N/AGap Up
GRCE
Grace Therapeutics
2.5508 of 5 stars
$3.39
+0.9%
$12.00
+254.0%
N/A$46.46MN/A-3.81N/APositive News
NBRV
Nabriva Therapeutics
N/AN/AN/AN/A$45.46M$35.59M0.0070
PRLD
Prelude Therapeutics
3.6967 of 5 stars
$0.84
+4.6%
$4.50
+434.4%
-84.4%$45.45M$7M-0.50120Positive News
ELYM
Eliem Therapeutics
N/A$1.51
+3.4%
N/A-82.9%$44.93MN/A-2.859Gap Down
KLRS
Kalaris Therapeutics
0.8669 of 5 stars
$2.42
+1.3%
N/AN/A$44.70MN/A0.00110Analyst Forecast
AADI
Aadi Bioscience
0.3745 of 5 stars
$1.80
-2.7%
$1.67
-7.4%
+28.0%$44.46M$25.07M-0.7940

Related Companies and Tools


This page (NASDAQ:BCDA) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners